UNSPSC 51131725: Epoprostenol or prostacyclin

This classification denotes a prostaglandin analogue and antihypertensive agent with the molecular formula C20H32O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DCR9Z582X0. European Medicines Agency schedules epoprostenol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06581MIG. The term EPOPROSTENOL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21. ).

EPOPROSTENOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Epoprostenol or prostacyclin bears US NLM identifiers UMLS ID C0033567 and NCI Concept Code C61748. SMILES: CCCCCC(C=CC1C(CC2C1CC(=CCCCC(=O)O)O2)O)O.

UNSPSC 51131725 Epoprostenol or prostacyclin is a Commodity code that designates a specific pharmaceutical agent used in the treatment of pulmonary hypertension and related vascular conditions. State and local governments procure this drug primarily through health departments, correctional facilities, and public hospital systems that provide direct patient care or maintain formularies for inmates and indigent populations. The code sees limited direct solicitation activity at the state and local level, as most procurement of specialized pharmaceuticals flows through established group purchasing agreements, state Medicaid programs, and centralized health-system contracts rather than through individual RFPs or IFBs.

The source provides no recent state or local opportunities aligned with this pharmaceutical code. The single posted opportunity in the dataset—Sourcewell RFP #061626 for Law Enforcement Equipment, due June 16, 2026—is unrelated to pharmaceutical procurement and represents a mismatch between the code tag and the actual scope of work being solicited. Epoprostenol procurement at the state and local level remains largely invisible in public solicitation channels, suggesting either consolidated purchasing through cooperative pharmaceutical agreements or procurement conducted outside traditional notice-posting mechanisms.